**
A honey-derived energy supplement is facing a nationwide recall following the discovery that it contains an unlabelled prescription medication for erectile dysfunction (ED). The U.S. Food and Drug Administration (FDA) announced the recall of the Ashfiat Alharamain Energy Support product on Tuesday, cautioning consumers about the potential health risks associated with its consumption.
Unforeseen Risks from Tadalafil
The product, manufactured by Akkarco LLC, a company based in Lorton, Virginia, was found to contain tadalafil, a substance approved by the FDA for treating male erectile dysfunction. This ingredient is classified as a phosphodiesterase-5 inhibitor, which is not permitted in dietary supplements. The FDA clarified that any product containing tadalafil that has not undergone regulatory evaluation is considered an “unapproved new drug.”
Health officials have expressed serious concerns about the implications of this undisclosed ingredient. Tadalafil is intended for use under medical supervision, and its presence in an over-the-counter supplement can lead to significant health risks. Potential side effects include cardiovascular complications, fluctuations in blood pressure, dizziness, headaches, and other adverse reactions, particularly for individuals with pre-existing health conditions or those taking certain medications.
Details of the Recall
The Ashfiat Alharamain Energy Support product was sold across the United States via various online platforms, including Amazon. The recall affects items packaged in glass bottles with an orange label, specifically identified with the batch number ENCOT24 and an expiration date of October 2028. As of now, the FDA has reported no incidents of adverse effects linked to this supplement.
Consumers who have purchased the affected product are strongly advised to cease usage immediately. If they experience any health issues or side effects, they should seek guidance from a healthcare professional. The FDA has also urged consumers to report any problems through its MedWatch adverse event reporting system, ensuring that any potential risks can be adequately monitored.
Company Response
In response to the recall, Akkarco LLC stated that it is actively working with its distribution partners to withdraw all impacted products from the market. The company has reaffirmed its commitment to maintaining customer trust and is implementing enhanced safety measures to prevent similar occurrences in the future.
The recall serves as a reminder of the importance of vigilance regarding dietary supplements and the necessity for consumers to be aware of what they are ingesting. The FDA’s actions aim to protect public health by ensuring that all products on the market meet safety and efficacy standards.
Why it Matters
This incident highlights a critical issue in the supplement industry, where products may contain undisclosed pharmaceutical ingredients that can pose serious health risks. As consumers increasingly turn to supplements for energy and wellness, the importance of regulatory oversight becomes paramount. The recall not only safeguards individual health but also serves as a reminder of the responsibility manufacturers have in ensuring transparency and safety. Awareness and caution are essential in navigating the supplement landscape, particularly when unregulated products can lead to severe health complications.
